Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections

Summary

Purpose of the study: • To obtain additional data on the efficacy and safety of Anaferon in the treatment of acute respiratory viral infections.

Timeline

Start

2018-10-09

Primary completion

2019-03-15

Completion

2019-03-15

Outcome

Met primary endpoint

registry MEAN Anaferon: 4.1 (Standard Deviation 1.6) days MEAN Placebo: 4.5 (Standard Deviation 1.5) days analysis (superiority test); Anaferon vs Placebo; p = 0.032; Wilcoxon (Mann-Whitney) NCT03707912 ↗

Drugs

Indications